News from isis pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 30, 2015, 16:30 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the...

Apr 29, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2015 Financial...

Apr 22, 2015, 16:06 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients...

Apr 10, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Mar 23, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx.  In this study,...

Mar 06, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $9 million milestone payment from Biogen Idec related to...

Mar 02, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the...

Feb 27, 2015, 09:30 ET
Isis Pharmaceuticals, Inc.

Isis Reports Financial Results and Highlights for 2014

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL) guidance and...

Feb 24, 2015, 10:46 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx.  In this study, healthy...

Feb 20, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:        Isis...

Feb 10, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the...

Feb 05, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating...

Feb 04, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Feb 03, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2...

Jan 14, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the...

Jan 08, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Company expects to significantly improve upon its 2014 financial...

Jan 06, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the appointment of Paula Soteropoulos as president and chief executive officer (CEO) of...

Jan 05, 2015, 18:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Sarah Boyce has joined the company as chief business officer.  In this...

Jan 05, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc....

Jan 02, 2015, 11:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...